S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:KNTE

Kinnate Biopharma Stock Forecast, Price & News

$19.51
-0.26 (-1.32%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.00
$21.68
50-Day Range
$18.74
$25.48
52-Week Range
$17.58
$48.75
Volume
102,060 shs
Average Volume
101,429 shs
Market Capitalization
$852.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive KNTE News and Ratings via Email

Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter.


Kinnate Biopharma logo

About Kinnate Biopharma

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. It develops KIN-2787, which is a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Diego, California.

Headlines

Kinnate Biopharma (NASDAQ:KNTE) Issues Quarterly Earnings Results
November 11, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KNTE
Fax
N/A
Employees
31
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$7.80 per share

Profitability

Net Income
$-35.76 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
24,382,000
Market Cap
$852.59 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/04/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
4/04/2022

MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

222nd out of 1,390 stocks

Pharmaceutical Preparations Industry

90th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Kinnate Biopharma (NASDAQ:KNTE) Frequently Asked Questions

Is Kinnate Biopharma a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kinnate Biopharma in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kinnate Biopharma stock.
View analyst ratings for Kinnate Biopharma
or view top-rated stocks.

When is Kinnate Biopharma's next earnings date?

Kinnate Biopharma is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for Kinnate Biopharma
.

How were Kinnate Biopharma's earnings last quarter?

Kinnate Biopharma Inc. (NASDAQ:KNTE) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.57) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.04.
View Kinnate Biopharma's earnings history
.

What price target have analysts set for KNTE?

7 brokerages have issued 12 month price targets for Kinnate Biopharma's stock. Their forecasts range from $32.00 to $60.00. On average, they anticipate Kinnate Biopharma's stock price to reach $47.67 in the next twelve months. This suggests a possible upside of 144.3% from the stock's current price.
View analysts' price targets for Kinnate Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Kinnate Biopharma's key executives?

Kinnate Biopharma's management team includes the following people:
  • Mr. Nima Farzan M.B.A., Pres, CEO & Director (Age 45, Pay $647.29k)
  • Mr. Mark A. Meltz, COO, Gen. Counsel, Treasurer & Sec. (Age 48, Pay $496.8k)
  • Dr. Eric Anthony Murphy Ph.D., Chief Scientific Officer (Age 46, Pay $545.81k)
  • Ms. Neha Krishnamohan, CFO, Principal Accounting Officer and Exec. VP of Corp. Devel.
  • Ms. Barbara Warren, VP of People & Culture
  • Dr. Richard Thomas Williams MBBS, Ph.D., Chief Medical Officer (Age 52)
  • Dr. Robert Kania Ph.D., Sr. VP of Drug Discovery
  • Mr. Eric Martin Ph.D., Sr. VP of Translational Medicine
  • Mr. Jason Hampson, VP & Head of Regulatory Affairs

When did Kinnate Biopharma IPO?

(KNTE) raised $170 million in an IPO on Thursday, December 3rd 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO.

What is Kinnate Biopharma's stock symbol?

Kinnate Biopharma trades on the NASDAQ under the ticker symbol "KNTE."

Who are Kinnate Biopharma's major shareholders?

Kinnate Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.29%), Boxer Capital LLC (4.23%), Citadel Advisors LLC (2.64%), Deerfield Management Company L.P. Series C (2.35%), Morgan Stanley (0.92%) and Geode Capital Management LLC (0.77%).
View institutional ownership trends for Kinnate Biopharma
.

Which major investors are selling Kinnate Biopharma stock?

KNTE stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Citadel Advisors LLC, Renaissance Technologies LLC, New York State Common Retirement Fund, and Victory Capital Management Inc..
View insider buying and selling activity for Kinnate Biopharma
or view top insider-selling stocks.

Which major investors are buying Kinnate Biopharma stock?

KNTE stock was acquired by a variety of institutional investors in the last quarter, including Boxer Capital LLC, BlackRock Inc., Morgan Stanley, EcoR1 Capital LLC, Millennium Management LLC, Geode Capital Management LLC, Goldman Sachs Group Inc., and HighVista Strategies LLC.
View insider buying and selling activity for Kinnate Biopharma
or or view top insider-buying stocks.

How do I buy shares of Kinnate Biopharma?

Shares of KNTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kinnate Biopharma's stock price today?

One share of KNTE stock can currently be purchased for approximately $19.51.

How much money does Kinnate Biopharma make?

Kinnate Biopharma has a market capitalization of $852.59 million.

How many employees does Kinnate Biopharma have?

Kinnate Biopharma employs 31 workers across the globe.

What is Kinnate Biopharma's official website?

The official website for Kinnate Biopharma is www.kinnate.com.

How can I contact Kinnate Biopharma?

The company can be reached via phone at 858-299-4699 or via email at [email protected].


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.